My­ovan­t's uter­ine fi­broid drug looks com­pet­i­tive in PhI­II — but can they van­quish mighty Ab­b­Vie?

Vivek Ra­maswamy’s My­ovant $MY­OV has close­ly matched its pos­i­tive first round of Phase III da­ta for their uter­ine fi­broid drug re­l­u­golix, set­ting up a head-to-head ri­val­ry with phar­ma gi­ant Ab­b­Vie as the lit­tle biotech steers to the mar­ket with a planned fil­ing in Q4.

Vivek Ra­maswamy

Here’s how My­ovant plans to pre­vail over the Ab­b­Vie $AB­BV em­pire.

In the study, 71.2% of women re­ceiv­ing once-dai­ly re­l­u­golix com­bi­na­tion ther­a­py achieved the clin­i­cal re­sponse they were look­ing for, com­pared to on­ly 14.7% in the con­trol arm. The da­ta com­fort­ably re­flect­ed the same out­comes in the first Phase III — 73.4% of women re­ceiv­ing once-dai­ly oral re­l­u­golix com­bi­na­tion ther­a­py achieved the re­spon­der cri­te­ria com­pared with 18.9% of women re­ceiv­ing place­bo — which will re­as­sure reg­u­la­tors that they are get­ting the care­ful­ly ran­dom­ized da­ta that qual­i­fies for the FDA’s gold stan­dard for suc­cess.

The suc­cess here, though, has to be com­pared with Ab­b­Vie’s elagolix, ap­proved last year for en­dometrio­sis and al­so on track for a date with the FDA on uter­ine fi­bro­sis — a con­di­tion that caus­es heavy men­stru­al bleed­ing among a por­tion of the pa­tients who have fi­broids. Ab­b­Vie’s Phase II­Is pro­duced clin­i­cal im­prove­ments for 76% and 68.5% of pa­tients.

Charles As­ch­er-Walsh Mount Sinai

A cou­ple of months ago, re­searchers pro­vid­ed an out­line of elagolix side ef­fects, though, that gave ex­perts in the field cau­tion about just how wide­ly sought af­ter the drug may be. In ad­di­tion to the loss of bone den­si­ty, the side ef­fects al­so in­clud­ed a pro­file sim­i­lar to menopause, with hot flash­es and night sweat. That could per­suade all but the most se­ri­ous cas­es to avoid the go­nadotropin-re­leas­ing hor­mone (GnRH) an­tag­o­nist.

“Women are will­ing to put up with [fi­broids] for years, so the idea of tak­ing a med­ica­tion that will have sig­nif­i­cant side ef­fects I don’t think is of­ten that pop­u­lar. [Symp­toms] are not as dra­mat­ic as the de­bil­i­tat­ing pain from en­dometrio­sis,” Charles As­ch­er-Walsh of Ic­ahn School of Med­i­cine at Mount Sinai told Med­Page To­day.

My­ovant, mean­while, said that there were no sig­nif­i­cant dif­fer­ences in terms of bone min­er­al den­si­ty with a sim­i­lar ef­fect in terms of hot flash­es — 5.6% for the drug ver­sus 3.9% for the place­bo.

Cowen’s Phil Nadeau sized it up and likes My­ovant’s chances of carv­ing out a block­buster fran­chise:

We think that to­day’s da­ta from LIB­ER­TY 2 cor­rob­o­rates the LIB­ER­TY 1 re­sults and con­firms that re­l­u­golix+add-back ther­a­py has a com­pet­i­tive pro­file with sim­i­lar ef­fi­ca­cy, some­what bet­ter tol­er­a­bil­i­ty, and im­proved con­ve­nience com­pared to Ab­b­Vie’s Orilis­sa. There­fore we con­tin­ue to be­lieve that re­l­u­golix has $1B+ sales po­ten­tial in uter­ine fi­borids.

Draw­ing dis­tinc­tions be­tween the two could be tough in this mar­ket for a com­pa­ny that doesn’t have near the same kind of com­mer­cial punch as Ab­b­Vie. But My­ovant has a com­pet­i­tive pro­file. In­vestors bid their shares up 10% this morn­ing in some­thing less than an en­thu­si­as­tic em­brace for the ri­val­ry ahead — then saw that melt away to a 1% drop in the ear­ly af­ter­noon.

So­cial im­age: Vivek Ra­maswamy at the US-Chi­na Bio­phar­ma In­no­va­tion and In­vest­ment Sum­mit in Shang­hai on Oc­to­ber 23, 2018; Cred­it: End­points News, Pharm­Cube

A New Fron­tier: The In­ner Ear

What happens when a successful biotech venture capitalist is unexpectedly diagnosed with a chronic, life-disrupting vertigo disorder? Innovation in neurotology.

That venture capitalist was Jay Lichter, Ph.D., and after learning there was no FDA-approved drug treatment for his condition, Ménière’s disease, he decided to create a company to bring drug development to neurotology. Otonomy was founded in 2008 and is dedicated to finding new drug treatments for the hugely underserved community living with balance and hearing disorders. Helping patients like Jay has been the driving force behind Otonomy, a company heading into a transformative 2020 with three clinical trial readouts: Phase 3 in Ménière’s disease, Phase 2 in tinnitus, and Phase 1/2 in hearing loss. These catalysts, together with others in the field, highlight the emerging opportunity in neurotology.
Otonomy is leading the way in neurotology
Neurotology, or the treatment of inner ear neurological disorders, is a large and untapped market for drug developers: one in eight individuals in the U.S. have moderate-to-severe hearing loss, tinnitus or vertigo disorders such as Ménière’s disease.1 With no FDA-approved drug treatments available for these conditions, the burden on patients—including social anxiety, lower quality of life, reduced work productivity, and higher rates of depression—can be significant.2, 3, 4

Joe Jimenez, Getty

Ex-No­var­tis CEO Joe Jimenez is tak­ing an­oth­er crack at open­ing a new chap­ter in his ca­reer — and that in­cludes a new board seat and a $250M start­up

Joe Jimenez is back.

The ex-CEO of Novartis has taken a board seat on Century Therapeutics, the Versant and Bayer-backed startup focused on coming up with a brand new twist on cell therapies for cancer — a field where Jimenez made his mark backing the first personalized CAR-T approved for use.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,800+ biopharma pros reading Endpoints daily — and it's free.

Credit: Shutterstock

Can we make the an­tibi­ot­ic mar­ket great again?

The standard for-profit model in drug development is straightforward. Spend millions, even billions, to develop a medicine from scratch. The return on investment (and ideally a tidy profit) comes via volume and/or price, depending on the disease. But the string of big pharma exits and slew of biotech bankruptcies indicate that the model is sorely flawed when it comes to antibiotics.

The industry players contributing to the arsenal of antimicrobials are fast dwindling, and the pipeline for new antibiotics is embarrassingly sparse, the WHO has warned. Drugmakers are enticed by greener pastures, compared to the long, arduous and expensive path to antibiotic approval that offers little financial gain as treatments are typically priced cheaply, and often lose potency over time as microbes grow resistant to them.

Top Har­vard chemist caught up in FBI’s 'T­hou­sand Tal­ents' drag­net, ac­cused of ly­ing about Chi­nese con­nec­tions, pay

The FBI’s probe into the alleged theft of R&D secrets by Chinese authorities has drawn Harvard’s top chemist into its net.

The agency accused Charles M. Lieber, who chairs the university’s chemistry and chemical biology department, with lying about his involvement in China’s Thousand Talents campaign, which was established as a way of drawing in innovators from around the world. And the scientist, 60, was charged with making false statements about his ties to China.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,800+ biopharma pros reading Endpoints daily — and it's free.

Eye­ing a trio of tri­al ini­ti­a­tions, Jim Wilson's gene ther­a­py start­up woos Bruce Gold­smith from Deer­field as CEO

Passage Bio — Jim Wilson’s self-described “legacy company” — has wooed a seasoned biotech executive to steer the clinical entry of its first three gene therapy programs.

Bruce Goldsmith jumps to the helm of Passage after a brief CEO stint at Civetta, a cancer-focused startup he helped launch while a venture partner at Deerfield. He takes over from OrbiMed partner and interim chief Stephen Squinto, who will now lead the R&D team.

The FTC and New York state ac­cuse Mar­tin Shkre­li of run­ning a drug mo­nop­oly. They plan to squash it — and per­ma­nent­ly ex­ile him

Pharma bro Martin Shkreli was jailed, publicly pilloried and forced to confront some lawmakers in Washington riled by his move to take an old generic and move the price from $17.50 per pill to $750. But through 4 years of controversy and public revulsion, his company never backed away from the price — left uncontrolled by a laissez faire federal policy on a drug’s cost.

Now the FTC and the state of New York plan to pry his fingers off the drug once and for all and open it up to some cheap competition. And their lawsuit is asking that Shkreli — with several years left on his prison sentence — be banned permanently from the pharma industry.

UP­DAT­ED: Ac­celeron res­ur­rects block­buster hopes for so­tater­cept with pos­i­tive PhII — and shares rock­et up

Acceleron $XLRN says that its first major trial readout of 2020 is a success.

In a Phase II study of 106 patients with pulmonary arterial hypertension (PAH), Acceleron’s experimental drug sotatercept hit its primary endpoint: a significant reduction in pulmonary vascular resistance. The drug also met three different secondary endpoints, including the 6-minute walking test.

“We’re thrilled to report such positive topline results from the PULSAR trial,” Acceleron CEO Habib Dable said in a statement. The company said in a conference call they plan on discussing a Phase III trial design with regulators.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,800+ biopharma pros reading Endpoints daily — and it's free.

Short at­tack­er Sahm Ad­ran­gi draws crosshairs over a fa­vorite of Sanofi’s new CEO — with PhII da­ta loom­ing

Sahm Adrang Kerrisdale

Kerrisdale chief Sahm Adrangi took a lengthy break from his series of biotech short attacks after his chief analyst in the field pulled up stakes and went solo. But he’s making a return to drug development this morning, drawing crosshairs over a company that’s one of new Sanofi CEO Paul Hudson’s favorite collaborators.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 70,800+ biopharma pros reading Endpoints daily — and it's free.

Amber Saltzman (Ohana)

Flag­ship's first ven­ture of 2020 is out, and it's all about sperm

A couple years ago, Amber Salzman got a call as she was returning East full-time after a two-year stint running a gene therapy company in California.

It was from someone at Flagship Pioneering, the deep-pocketed biotech venture firm. They had a new company with a new way of thinking about sperm. It had been incubating for over a year, and now they wanted her to run it.

“It exactly fit,” Salzman told Endpoints News. “I just thought I had to do something.”